Literature DB >> 34019660

Rare variants in triglycerides-related genes increase pancreatitis risk in multifactorial chylomicronemia syndrome.

Martine Paquette1, Julie Amyot2, Manon Fantino1, Alexis Baass1,3, Sophie Bernard1,4.   

Abstract

CONTEXT: Severe hypertriglyceridemia (fasting triglycerides (TG) concentration ≥ 10 mmol/L) can be caused by multifactorial chylomicronemia syndrome (MCS) or familial chylomicronemia syndrome (FCS). Both conditions are associated with an increased risk of acute pancreatitis. The clinical differences between MCS patients with or without a rare variant in TG-related genes have never been studied.
OBJECTIVES: To compare the clinical and biochemical characteristics of FCS, positive-MCS patients and negative-MCS patients, as well as to investigate the predictors of acute pancreatitis in MCS patients.
METHODS: All patients referred at the clinic for severe hypertriglyceridemia underwent genetic testing for the 5 canonical genes involved in TG metabolism (LPL, APOC2, GPIHBP1, APOA5, and LMF1) using next-generation sequencing.
RESULTS: A total of 53 variant negative-MCS, 22 variant positive-MCS and 28 FCS subjects were included in this retrospective cross-sectional study. A significant difference was observed in the prevalence of pancreatitis (9%, 41% and 61%) and multiple pancreatitis (6%, 23% and 46%) in the negative-MCS, the positive-MCS and the FCS groups, respectively (P<0.0001). Predictors of pancreatitis among MCS subjects included the presence of a rare variant, lower apolipoprotein B, as well as a higher GGT, maximal TG value and fructose consumption.
CONCLUSION: We observed that the MCS individuals who carried a rare variant have an intermediate phenotype between FCS and negative-MCS subjects. Since novel molecules such as the antisense oligonucleotide against APOC3 mRNA showed high efficacy in reducing TG levels in patients with multifactorial chylomicronemia, identification of higher-risk MCS patients that would benefit from additional treatment is primordial.
© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  Multifactorial chylomicronemia; familial chylomicronemia syndrome; fructose; pancreatitis; severe hypertriglyceridemia

Year:  2021        PMID: 34019660     DOI: 10.1210/clinem/dgab360

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  3 in total

1.  Efficacy and safety of the apolipoprotein C-III inhibitor Volanesorsen: a systematic evaluation and meta-analysis.

Authors:  Yonglang Cheng; Tongxi Li; Peng Tan; Yichao Du; Zhiwei Huang; Hao Shi; Tianying Cai; Yifan Chen; Wenguang Fu
Journal:  Endocrine       Date:  2022-03-17       Impact factor: 3.633

Review 2.  The Evolving Story of Multifactorial Chylomicronemia Syndrome.

Authors:  Martine Paquette; Sophie Bernard
Journal:  Front Cardiovasc Med       Date:  2022-04-14

3.  Case Report: Genetic Analysis of PEG-Asparaginase Induced Severe Hypertriglyceridemia in an Adult With Acute Lymphoblastic Leukaemia.

Authors:  Arcangelo Iannuzzi; Mario Annunziata; Giuliana Fortunato; Carola Giacobbe; Daniela Palma; Alessandro Bresciani; Emilio Aliberti; Gabriella Iannuzzo
Journal:  Front Genet       Date:  2022-02-14       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.